UNCY vs. CARA, NXTC, LEXX, SNSE, NBRV, EYEN, BOLT, IMRX, VYNE, and XLO
Should you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include Cara Therapeutics (CARA), NextCure (NXTC), Lexaria Bioscience (LEXX), Sensei Biotherapeutics (SNSE), Nabriva Therapeutics (NBRV), Eyenovia (EYEN), Bolt Biotherapeutics (BOLT), Immuneering (IMRX), VYNE Therapeutics (VYNE), and Xilio Therapeutics (XLO). These companies are all part of the "pharmaceutical preparations" industry.
Unicycive Therapeutics (NASDAQ:UNCY) and Cara Therapeutics (NASDAQ:CARA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, community ranking, risk and dividends.
Unicycive Therapeutics has a beta of 2.72, indicating that its stock price is 172% more volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.
40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 44.7% of Cara Therapeutics shares are held by institutional investors. 42.0% of Unicycive Therapeutics shares are held by company insiders. Comparatively, 3.1% of Cara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Cara Therapeutics had 2 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 12 mentions for Cara Therapeutics and 10 mentions for Unicycive Therapeutics. Cara Therapeutics' average media sentiment score of -0.13 beat Unicycive Therapeutics' score of -0.25 indicating that Cara Therapeutics is being referred to more favorably in the news media.
Unicycive Therapeutics currently has a consensus target price of $5.30, indicating a potential upside of 388.48%. Cara Therapeutics has a consensus target price of $9.93, indicating a potential upside of 1,216.37%. Given Cara Therapeutics' higher possible upside, analysts clearly believe Cara Therapeutics is more favorable than Unicycive Therapeutics.
Unicycive Therapeutics has a net margin of 0.00% compared to Cara Therapeutics' net margin of -723.49%. Unicycive Therapeutics' return on equity of 0.00% beat Cara Therapeutics' return on equity.
Unicycive Therapeutics has higher earnings, but lower revenue than Cara Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Cara Therapeutics received 647 more outperform votes than Unicycive Therapeutics when rated by MarketBeat users. Likewise, 75.00% of users gave Cara Therapeutics an outperform vote while only 65.52% of users gave Unicycive Therapeutics an outperform vote.
Summary
Unicycive Therapeutics and Cara Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Unicycive Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Unicycive Therapeutics Competitors List
Related Companies and Tools
